[go: up one dir, main page]

WO2002013764A3 - Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae - Google Patents

Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae Download PDF

Info

Publication number
WO2002013764A3
WO2002013764A3 PCT/US2001/025466 US0125466W WO0213764A3 WO 2002013764 A3 WO2002013764 A3 WO 2002013764A3 US 0125466 W US0125466 W US 0125466W WO 0213764 A3 WO0213764 A3 WO 0213764A3
Authority
WO
WIPO (PCT)
Prior art keywords
herpes virus
infection
present
treating
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/025466
Other languages
English (en)
Other versions
WO2002013764A2 (fr
Inventor
John Docherty
Chun-Che Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeast Ohio Medical University
Kent State University
Original Assignee
Northeast Ohio Medical University
Kent State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeast Ohio Medical University, Kent State University filed Critical Northeast Ohio Medical University
Priority to AU2001288250A priority Critical patent/AU2001288250A1/en
Priority to CA002423337A priority patent/CA2423337A1/fr
Priority to JP2002518912A priority patent/JP2004505998A/ja
Priority to EP01967971A priority patent/EP1311254A2/fr
Publication of WO2002013764A2 publication Critical patent/WO2002013764A2/fr
Publication of WO2002013764A3 publication Critical patent/WO2002013764A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un procédé permettant d'inhiber la formation de particules infectieuses du virus de l'herpès, particulièrement les particules infectieuses de l'herpes simplex virus (HSV), dans une cellule hôte. Le procédé implique l'administration d'une quantité efficace d'un tolane hydroxylé, particulièrement d'un tolane polyhydroxylé, à une cellule hôte infectée par le virus de l'herpès. La présente invention concerne également un procédé permettant de traiter une infection due au virus de l'herpès, particulièrement une infection à HSV. Ce procédé consiste à administrer une composition topique comprenant une quantité thérapeutiquement efficace d'un tolane hydroxylé à un site infecté par le virus de l'herpès. La présente invention concerne également une composition topique permettant de traiter une infection au virus de l'herpès, sélectionnée dans le groupe comprenant une infection à HSV, une infection à cytomégalovirus, et une infection à virus varicella zoster. La présente invention concerne également un procédé de traitement d'un sujet infecté par Neisseria gonorrhea.
PCT/US2001/025466 2000-08-15 2001-08-15 Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae Ceased WO2002013764A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001288250A AU2001288250A1 (en) 2000-08-15 2001-08-15 Methods for treating subjects infected with a herpes virus or neisseria gonorrheae
CA002423337A CA2423337A1 (fr) 2000-08-15 2001-08-15 Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae
JP2002518912A JP2004505998A (ja) 2000-08-15 2001-08-15 ヘルペスウイルスまたはＮｅｉｓｓｅｒｉａｇｏｎｏｒｒｈｏｅａｅに感染した患者を処置する方法
EP01967971A EP1311254A2 (fr) 2000-08-15 2001-08-15 Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou i neisseria gonorrheae /i

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22560900P 2000-08-15 2000-08-15
US60/225,609 2000-08-15

Publications (2)

Publication Number Publication Date
WO2002013764A2 WO2002013764A2 (fr) 2002-02-21
WO2002013764A3 true WO2002013764A3 (fr) 2002-07-25

Family

ID=22845537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025466 Ceased WO2002013764A2 (fr) 2000-08-15 2001-08-15 Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae

Country Status (6)

Country Link
US (2) US6599945B2 (fr)
EP (1) EP1311254A2 (fr)
JP (1) JP2004505998A (fr)
AU (1) AU2001288250A1 (fr)
CA (1) CA2423337A1 (fr)
WO (1) WO2002013764A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2423337A1 (fr) * 2000-08-15 2002-02-21 Northeastern Ohio Universities College Of Medicine Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae
US20070082035A1 (en) * 2005-10-06 2007-04-12 New York Blood Center, Inc. Anti-infective hygiene products based on cellulose acetate phthalate
US7678819B2 (en) 2006-12-07 2010-03-16 The Trustees Of The University Of Pennsylvania Acetylene derivatives and their use for binding and imaging amyloid plaques
WO2008157787A2 (fr) * 2007-06-20 2008-12-24 Kent State University Tolans hydroxylés et composés apparentés dans le traitement du cancer
US8680142B2 (en) * 2007-06-20 2014-03-25 Kent State University Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer
EP2456306A4 (fr) 2009-07-20 2012-12-26 Summa Health System Vitamine c et vitamine k, et compositions en contenant utilisables dans le cadre du traitement de l'ostéolyse ou du prolongement de la durée de vie d'un implant prothétique
CN102625792A (zh) * 2009-07-22 2012-08-01 帝斯曼知识产权资产管理有限公司 用于生产被取代的富电子二苯乙炔的方法
WO2014074765A2 (fr) 2012-11-08 2014-05-15 Summa Health System Vitamine c, vitamine k, un polyphénol et leurs combinaisons pour la cicatrisation des plaies
SG11201707919QA (en) * 2015-04-08 2017-10-30 Biomendics Llc Formulation and process for modulating wound healing
EP3249406A1 (fr) * 2016-05-27 2017-11-29 PerkinElmer Cellular Technologies Germany GmbH Procede de determination du nombre de foyers d'infection d'une culture cellulaire
AU2018306420B2 (en) * 2017-07-27 2024-02-15 BioMendics, LLC Substituted tolans for the modulation of microbial colonization
CN119707643A (zh) * 2023-09-28 2025-03-28 德明药泰生物技术（深圳）有限公司 AhR调节剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928399A (en) * 1973-01-12 1975-12-23 Thomson Csf Nematic liquid crystal 4-methoxy-4{40 -hydroxytolan esters
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280030C (fr)
US4001137A (en) * 1971-08-07 1977-01-04 Merck Patent Gesellschaft Mit Beschrankter Haftung Nematic compounds and mixtures
US4153509A (en) * 1977-10-17 1979-05-08 Union Carbide Corporation Microbial production of hydroxylated biphenyl compounds
DD280030A1 (de) * 1989-02-24 1990-06-27 Bitterfeld Chemie Mittel zum schutz von kultur- und nutzpflanzen gegen viren
US5420361A (en) * 1992-02-05 1995-05-30 Bio-Technical Resources Formulation of and dehydration of hydroxylated diphenyl acetylenes
CA2423337A1 (fr) * 2000-08-15 2002-02-21 Northeastern Ohio Universities College Of Medicine Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928399A (en) * 1973-01-12 1975-12-23 Thomson Csf Nematic liquid crystal 4-methoxy-4{40 -hydroxytolan esters
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles

Also Published As

Publication number Publication date
US7094809B2 (en) 2006-08-22
US20030203974A1 (en) 2003-10-30
AU2001288250A1 (en) 2002-02-25
US6599945B2 (en) 2003-07-29
EP1311254A2 (fr) 2003-05-21
JP2004505998A (ja) 2004-02-26
WO2002013764A2 (fr) 2002-02-21
CA2423337A1 (fr) 2002-02-21
US20020103262A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
WO2000012534A3 (fr) Procede permettant d'inhiber la formation de particules infectieuses de l'herpesvirus
WO2002013764A3 (fr) Procedes permettant le traitement de sujets infectes par un virus de l'herpes ou neisseria gonorrheae
DE60027029T2 (de) Kombinierte impfstoffzusammensetzungen
Stanberry et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes
DE69933200T2 (de) Kombinierte impfstoffzusammensetzungen
DE60027440T2 (de) Impfstoff gegen hbv und hpv
WO2001045737A3 (fr) Mutants de glycoproteine c du virus herpes simplex 1 destines au traitement de la croissance de cellules hyperproliferatives non desirees
BRPI0107737B1 (pt) vírus do herpes simplex 1 (hsv1), uso do hsv1, e, composição farmacêutica
NO20010576L (no) Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav
BR9907283A (pt) Vìrus do herpes simples, uso de um vìrus do herpes simples, composição farmacêutica, e, processos para estudar a função de gene heterólogo em uma célula de mamìfero e para produzir um vìrus do herpes simples
WO2001090121A3 (fr) Methodes et compositions permettant de traiter le virus de l'hepatite c
JP2003520044A5 (fr)
BR0115511A (pt) Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo
HUP9902791A2 (hu) Polinukleotid-vakcinakészítmény, elsősorban szarvasmarhák légzőszervi kórképei ellen
JP2003526670A5 (fr)
WO1990002803A3 (fr) Vaccins antiviraux
Grussendorf-Conen et al. Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities
BR0209161A (pt) Composição de vacina, kit de vacinação, método de tratamento médico, uso de um antìgeno de hpv, e, métodos para preparar uma vacina e para diminuir a transmissão viral do hiv
Romanowski et al. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model
WO2002012288A3 (fr) Vaccination contre l'herpesvirus associe a une cellule hote
WO2002026728A3 (fr) Procedes antiviraux et composes
US6355226B1 (en) Topical treatment of skin disease and eye afflictions
WO2001022950A3 (fr) Methode de traitement ou de prevention d'infections virales au moyen d'analogues nucleosidiques
Ramachandran et al. Potential prophylactic and therapeutic vaccines for HSV infections
Bernstein et al. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002518912

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001967971

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001288250

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2423337

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001967971

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001967971

Country of ref document: EP